However, more evidence and clinical trials are needed to evaluate the causes of larotrectinib resistance and the efficacy and safety of the combination of TRK inhibitors and EGFR inhibitors in the treatment of NSCLC patients harboring TPR-NTRK1 fusion and EGFR mutations. This evidence concerns the gene NTRK1 and non-small cell lung carcinoma.